Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Harvard Business School
Johnson and Johnson
Express Scripts
AstraZeneca

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

ORAVERSE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Oraverse patents expire, and what generic alternatives are available?

Oraverse is a drug marketed by Septodont Holding and is included in one NDA. There are five patents protecting this drug.

This drug has thirty-four patent family members in twenty countries.

The generic ingredient in ORAVERSE is phentolamine mesylate. There are four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.

Drug patent expirations by year for ORAVERSE
Drug Prices for ORAVERSE

See drug prices for ORAVERSE

Recent Clinical Trials for ORAVERSE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dalhousie UniversityPhase 4
León FormaciónN/A
Dalhousie UniversityN/A

See all ORAVERSE clinical trials

Pharmacology for ORAVERSE
Synonyms for ORAVERSE
134P201
2-[N-(m-Hydroxyphenyl)-p-toluidinomethyl]imidazoline Methanesulfonate
2-[N-(m-Hydroxyphenyl)-p-toluidinomethyl]imidazoline, methanesulfonate
3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(p-tolyl)amino)phenol methanesulfonate
3-[(2-imidazolin-2-ylmethyl)(4-methylphenyl)amino]phenol, methanesulfonic acid
3-[[(4,5-Dihydro-1H-imidazol-2- yl)methyl](4-methylphenyl)-amino]phenol mesylate
3-[[(4,5-Dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)-amino]phenol mesylate
3-[[(4,5-Dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol methanesulfonate
3-[4,5-dihydro-1H-imidazol-2-ylmethyl-(4-methylphenyl)amino]phenol; methanesulfonic acid
3-[N-(2-Imidazolin-2-ylmethyl)-p-toluidino]phenol methanesulphonate
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methyl-anilino]phenol; methanesulfonic acid
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol; methanesulfonic acid
3-[N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic acid
4CA-1013
50-60-2 (Parent)
65-28-1
A828197
A835046
AB0014005
AB2000443
AC-7472
AC1L3M27
AKOS007930193
AN-8957
AS-13800
BC200362
BCP09845
C17H19N3O.CH4O3S
C18H23N3O4S
CCG-222286
CCRIS 9022
CHEMBL1200873
CPD000059054
CS-2419
CTK8G2357
D00509
DTXSID60215315
EINECS 200-604-6
EU-0100982
FT-0603267
HMS2233A24
HMS3263E05
HMS3373D03
HMS3655B13
HY-B0362A
I14-0396
J10339
K062
KS-00000XQY
Lopac-P-7561
LP00982
LS-104726
m-(N-(2-Imidazolin-2-ylmethyl)-p-toluidino)phenol monomethanesulfonate (salt)
MCULE-3770473461
MFCD00134201
MLS000069487
MLS001076484
MolPort-003-959-154
NCGC00016195-01
NCGC00016195-02
NCGC00094282-01
NCGC00261667-01
NV-101
Opera_ID_1599
P 7561
P1985
Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt)
Phenol, m-(N-(2-imidazolin-2-ylmethyl)-p-toluidino)-, monomethanesulfonate (salt)
Phentolamine (mesylate)
phentolamine mesilate
Phentolamine mesilate (JAN/INN)
Phentolamine mesilate [INN:BAN]
Phentolamine mesilate for system suitability, European Pharmacopoeia (EP) Reference Standard
Phentolamine mesilate, British Pharmacopoeia (BP) Reference Standard
Phentolamine mesilate, European Pharmacopoeia (EP) Reference Standard
Phentolamine Meslate,(S)
Phentolamine mesylate
Phentolamine mesylate (USP)
Phentolamine mesylate [USAN]
Phentolamine mesylate [USP]
Phentolamine Mesylate, Pharmaceutical Secondary Standard; Certified Reference Material
Phentolamine mesylate, United States Pharmacopeia (USP) Reference Standard
Phentolamine methanesulfonate
Phentolamine methanesulfonate salt
Phentolamine methanesulfonate salt, >=98% (TLC), powder
Phentolamine methanesulphonate
Phentolamine, methyl sulfonate
REGID_for_CID_91430
Regitin mesylate
Regitin methanesulphonate
Regitine (TN)
Regitine mesylate
Regitine methanesulfonate
s2038
SAM002703130
SCHEMBL40852
SMR000059054
SR-01000000055
SR-01000000055-3
ST057364
SW196637-3
Tox21_500982
UNII-Y7543E5K9T
Vasofem
Vasomax
VZ33629
W-104799
Y7543E5K9T
Z-Max

US Patents and Regulatory Information for ORAVERSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Baxter
Mallinckrodt
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.